EHS
EHS

FDA approves first drug for treatment of adult AML patients with specific genetic mutation



The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation.



Source link

EHS
Back to top button